Webcast Alert: Aastrom Announces Its Third Quarter Investor Conference Call

  
    
  
  
    
      Aastrom Biosciences, Inc. (NASDAQ: ASTM) announces the following Webcast:
    
    
      What: Aastrom Biosciences, Inc. 3rd Quarter Fiscal Year 2007 Investor 
      Conference Call
    
    
      When: Tuesday, May 8, 2007 @ 9:00 am (EDT)
    
    
      Where: http://www.vcall.com/IC/CEPage.asp?ID=115723
    
    
      How:
    
    
      • For live Internet access, simply log 
      on to the web at the address above.
    
    
      • For phone access, interested parties 
      should call toll-free [phone] before the start of the call to 
      register and identify themselves as registrants of the “Aastrom 
      Conference Call”. Any registered caller on the 
      toll-free line may ask for call operator for directions to be placed in 
      the queue for the Question & Answer session. If calling from outside the 
      U.S., please use the international phone number [phone].
    
    
      • To download the podcast, simply log 
      on to the web at the address above.
    
    
      Contact: Investor Relations Department, [phone] or [e-mail]
    
    
      If you are unable to participate during the live call, the webcast will 
      be available for replay at http://www.investorcalendar.com/ 
      for 60 days. Through May 18, 2007, the audio replay of the call will be 
      available by dialing toll-free [phone], or from outside the U.S. 
      [phone]. When prompted on the phone, the Account # is: 286, and 
      the Conference ID# is: 237442.
    
    
      Aastrom is a regenerative medicine company developing autologous cell 
      products for the repair or regeneration of multiple human tissues, based 
      on its proprietary Tissue Repair Cell (TRC) Technology. Aastrom's 
      TRC-based products are a unique cell mixture of stem and progenitor 
      cells, produced from a small amount of bone marrow taken from the 
      patient. TRC-based products have been used in over 250 patients, and are 
      currently in clinical trials for bone regeneration (osteonecrosis of the 
      femoral head, long bone fractures and spine fusion) and vascular 
      regeneration (critical limb ischemia) applications. Aastrom has reported 
      positive interim clinical trial results suggesting both the clinical 
      safety and the ability of TRC products to promote healing in bone 
      regeneration applications. The Company is also developing programs for 
      TRC-based therapies to address cardiac and neural regeneration 
      indications. TRCs have received Orphan Drug Designation from the FDA for 
      use in the treatment of osteonecrosis of the femoral head and the 
      treatment of dilated cardiomyopathy, a severe chronic disease of the 
      heart.
    
    
      For more information, visit Aastrom’s website 
      at www.aastrom.com. (astmc)